slides · global inventory
Chart
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 78,138
Current window 63,661-63,690
Pages 2,605
Rows per page 30
Component
63,661-63,690 of 78,138
06
Aeglea BioTherapeutics | Investor Presentation Deck | 56 slidesAeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
07
The slide uses a donut chart to illustrate market growth from 2021 to 2028.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
08
The chart uses a visual metaphor of an arrow pointing from current standard of care (SOC) to a higher efficacy/convenience target.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Problem (Identify pain)1 hit
10
The slide uses a visual representation of an antibody molecule with callouts to specific engineering improvements, supported by a scatter plot showing clinical precedent for half-life extension.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Aha Moment1 hit
11
Uses a visual metaphor of antibody combination to explain the therapeutic strategy.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Aha Moment1 hit
12
The slide uses a Venn diagram to represent the intersection of genetic targets and a bar chart to demonstrate the efficacy of patient selection.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Aha Moment1 hit
14
The slide uses a Gantt-style layout to show progress across Discovery, IND-Enabling, and Clinical stages.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Aha Moment1 hit
16
The chart uses a vertical axis to imply a safety spectrum (Safest to Riskiest) and a horizontal axis for efficacy (clinical remission %).Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Aha Moment1 hit
20
The chart shows dose-response curves for three donors; the table summarizes the calculated EC50 values.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
21
The chart uses a log-linear scale for concentration over time to demonstrate the beta-elimination phase.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
22
The slide uses a bar chart to compare pharmacokinetic properties between a proprietary drug candidate (SPY001) and a competitor (Entyvio).Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
24
The slide uses a bar chart to show benchmark data alongside a specific exposure-response analysis for vedolizumab.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
25
Data from GEMINI 1 study; highlights that higher exposure does not necessarily correlate with higher remission rates.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
26
The slide uses a 2x2 grid to summarize the program's value proposition.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
27
The slide uses peer benchmarking to justify valuation growth expectations based on clinical trial phases.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
27
Excludes Credit Suisse. Includes specific commentary on Global Markets and Global Banking performance drivers.UBS | Results Presentation Deck | 41 slides · UBS
Conference presentation Investor relations Beat · Solution & ApproachLoop · Maturity Curve1 hit
28
The chart uses a waterfall structure to show the impact of acquisition-related effects and other adjustments on the reported loss.UBS | Results Presentation Deck | 41 slides · UBS
Conference presentation Investor relations Beat · Solution & Approach1 hit
29
Includes a waterfall chart for pre-tax income and a summary table of revenues and expenses.UBS | Results Presentation Deck | 41 slides · UBS
Conference presentation Investor relations Beat · Solution & Approach1 hit
30
The slide uses a waterfall bridge to explain the transition from a negative 2Q23 PBT to a projected break-even/positive state.UBS | Results Presentation Deck | 41 slides · UBS
Conference presentation Investor relations Beat · Solution & Approach1 hit
37
The slide uses a waterfall chart to explain the variance between projected and actual negative goodwill for the Credit Suisse acquisition.UBS | Results Presentation Deck | 41 slides · UBS
Conference presentation Investor relations 1 hit
38
The slide compares RWA (excl. operational risk) and LRD metrics across five asset classes: Equities, Macro, Loans, Securitized products, and Credit/HQLA.UBS | Results Presentation Deck | 41 slides · UBS
Conference presentation Investor relations 1 hit
39
The chart illustrates how Credit Suisse's 2Q23 AuM of 1,357bn is adjusted to reach 1,220bn in UBS invested assets.UBS | Results Presentation Deck | 41 slides · UBS
Conference presentation Investor relations 1 hit
12
The slide uses a combination of a bubble chart (representing market segments) and a bar chart (representing TAM growth).Vivid Seats | Investor Presentation Deck | 22 slides · Vivid Seats
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
16
2020 is omitted from the timeline.Vivid Seats | Investor Presentation Deck | 22 slides · Vivid Seats
Pitch deck Investor relations 1 hit
16
The slide explains the dual-class structure (Class A and Class B) and how they relate to economic interest and EPS calculations.Vivid Seats | Results Presentation Deck | 19 slides · Vivid Seats
Conference presentation Investor relations 1 hit
18
The chart includes a trend line showing a 3-4% CAGR over the period.Vivid Seats | Results Presentation Deck | 19 slides · Vivid Seats
Conference presentation Investor relations 1 hit
08
The slide highlights the growth of the skincare segment, showing both absolute revenue and percentage contribution to the total.Yatsen | Results Presentation Deck | 17 slides · Yatsen Holding Limited
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
10
The chart highlights the period of store count reduction during 2022.Yatsen | Results Presentation Deck | 17 slides · Yatsen Holding Limited
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
14
The chart shows a breakdown of R&D, G&A, S&M, and Fulfillment expenses.Yatsen | Results Presentation Deck | 17 slides · Yatsen Holding Limited
Conference presentation Investor relations Beat · Action1 hit
16
The chart displays two distinct metrics: a running balance (top row) and quarterly cashflow (bars).Yatsen | Results Presentation Deck | 17 slides · Yatsen Holding Limited
Conference presentation Investor relations Beat · Action1 hit